Leading industry award recognizes CST for contributions to the life sciences industry, including single cell assay technology innovation and genetics research
Danvers, MA, USA, April 22, 2025 – Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced that it has been named CiteAb’s Recombinant Antibody Supplier of the Year, which recognizes the company with the most citations for its recombinant antibodies over the past year. CST also received this distinction in 2022, the first and only other time the award has been presented in this category.
“Recombinant antibody technology is the present and future of reliable antibody reagents,” says Roby Polakiewicz, Chief Scientific Officer at CST. “Due to gene cloning, recombinant antibodies are precise and reproducible, and their synthetic origin means that lot-to-lot variability is a thing of the past. At CST, we’re fully committed to recombinant antibodies, and nearly 99% of our new antibodies are created using recombinant DNA technology.”
CiteAb analyzes empirical citation data to identify antibody suppliers making an impact in key areas across life sciences. Drawing from over 380 global antibody suppliers and nearly 8 million antibodies, CST stands out for having significantly more antibodies on CiteAb’s top reagent lists than any other antibody company, ever.
Rhys Williams, Head of Antibody Data at CiteAb, said: "Recombinant antibody citations have been increasing steadily over the years. They offer benefits to scientists such as lot-to-lot consistency, contributing to more reproducible experiments. This award win goes to show Cell Signaling Technology's commitment to supporting scientists in the recombinant antibody space."
In response to the scientific reproducibility crisis, researchers are demanding more comprehensive antibody validation testing data from manufacturers. CST pioneered application-specific validation, which includes using a unique set of experiments to confirm antibody specificity, sensitivity, and selectivity in the context in which they will be used by researchers. This rigorous testing data is readily available in the CST product catalog for all reagents. With more citations per antibody than any other vendor—including for recombinant antibodies—CST continues to be the company researchers turn to most frequently when they need highly validated, reliable, and specific antibodies for their research projects destined for publication.
In addition to the Recombinant Antibody Supplier of the Year award, CST received two additional honors in the 2025 CiteAb Awards:
The CiteAb Awards were founded in 2014 to recognize life sciences providers making a significant impact on the industry in terms of antibody data, validation testing, and reproducibility. CST has a long history of strong performance in awards and recognition by CiteAb, including being the Antibody Supplier of the Decade.
About Cell Signaling Technology
Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. CST is a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our customers, our communities, and our planet. cellsignal.com
CST Media and Press
Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Senior Director, Global Marketing Communications
Phone: +1-978-880-3334
Email: [email protected]
